Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 8, 2013 - Issue
Submit an article Journal homepage
74
Views
8
CrossRef citations to date
0
Altmetric
Review

Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review

Erminia Ridolo1 Department of Clinical and Experimental Medicine, University of Parma, ParmaCorrespondence[email protected]
,
Marcello Montagni1 Department of Clinical and Experimental Medicine, University of Parma, Parma
,
Elisa Olivieri1 Department of Clinical and Experimental Medicine, University of Parma, Parma
,
Gian Galeazzo Riario-Sforza2 Pulmonary Rehabilitation Unit, ICP Hospital, Milan, Italy
&
Cristoforo Incorvaia2 Pulmonary Rehabilitation Unit, ICP Hospital, Milan, Italy
Pages 425-432 | Published online: 18 Sep 2013

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Erminia Ridolo, Irene Pellicelli, Bruna Gritti & Cristoforo Incorvaia. (2019) Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide. Patient Preference and Adherence 13, pages 145-150.
Read now
Cristoforo Incorvaia, Marcello Montagni, Elena Makri & Erminia Ridolo. (2016) New combinations in the treatment of COPD: rationale for aclidinium–formoterol. Therapeutics and Clinical Risk Management 12, pages 209-215.
Read now
Cristoforo Incorvaia, Marcello Montagni, Elena Makri, Gian Galeazzo Riario-Sforza & Erminia Ridolo. (2016) Striving for optimal bronchodilation: focus on olodaterol. International Journal of Chronic Obstructive Pulmonary Disease 11, pages 439-444.
Read now

Articles from other publishers (5)

M. Reza Maleki-Yazdi, Ekkehard Beck, Alan L. Hamilton, Lawrence Korducki, Paul Koker & Charles Fogarty. (2015) A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease. Respiratory Medicine 109:5, pages 596-605.
Crossref
Erminia Ridolo, Marcello Montagni, Gian Galeazzo Riario-Sforza, Marco Baroni & Cristoforo Incorvaia. (2015) Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety. Therapeutic Advances in Respiratory Disease 9:2, pages 49-55.
Crossref
Toshio Nakaki. 2015. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions 163 174 .
Ronald Anderson, Annette J. Theron, Helen C. Steel, Chrisna Durandt, Gregory R. Tintinger & Charles Feldman. (2014) The Beta-2-Adrenoreceptor Agonists, Formoterol and Indacaterol, but Not Salbutamol, Effectively Suppress the Reactivity of Human Neutrophils In Vitro . Mediators of Inflammation 2014, pages 1-9.
Crossref
Elena Bozzola, Mauro Bozzola, Salvatore Barberi, Renato Cutrera & Alberto Villani. (2013) Safety and Potential Side Effects of ß2-Agonists: A Still Debated Question . International Journal of Pediatrics and Child Health 1:1, pages 4-10.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.